Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer

Angioli, Roberto; Luvero, Daniela; Plotti, F.; Zullo, Marzio Angelo; Damiani, Paul; Angelucci, Michela; Ricciardi, Roberto; Aloisi, Alessia; Scaletta, G.; Panici, Pierluigi Benedetti

doi:10.1016/j.ygyno.2011.12.004

Cited by 20 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with LACC (group 2) received two or three cycles of treatment with paclitaxel (175 mg/m 2 ; Taxol, Corden Pharma Latina, Sermoneta, Italy) plus cisplatin (75 mg/m 2 ; Hospira, Melbourne, Victoria) [12,13]. The tumor response was analyzed in accordance with the revised Response Evaluation Criteria in Solid Tumors (RECIST) 2009 guidelines [14].…”

Section: Methodsmentioning

confidence: 99%

Robotic nerve-sparing radical hysterectomy for locally advanced cervical cancer after neoadjuvant chemotherapy

Liu

et al. 2015

International Journal of Gynecology & Obstetrics

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Robotic nerve-sparing radical hysterectomy for locally advanced cervical cancer after neoadjuvant chemotherapy

Liu

et al. 2015

International Journal of Gynecology & Obstetrics

View full text Add to dashboard Cite

show abstract

“…Among these variables, lower third vaginal involvement was associated with a greater risk of poor prognosis compared with bladder/rectal involvement, resulting in uncertainty regarding the reliability of lower third vaginal and bladder/rectal involvement as requirements for FIGO stages IIIB and IVA, respectively. Improvements in palliative treatment, including percutaneous nephrostomy, diversion cystostomy/colostomy and neoadjuvant chemotherapy, may have affected these survival results (23)(24)(25).…”

mentioning

confidence: 99%

Tumor size and lymph node status determined by imaging are reliable factors for predicting advanced cervical cancer prognosis

et al. 2015

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the prognostic role of a number of clinical factors in advanced cervical cancer patients. Patients (n=157) with stage IIA-IIB cervical cancer treated at four Hallym Medical Centers in South Korea (Hallym University Sacred Heart Hospital; Kangnam Sacred Heart Hospital; Chuncheon Sacred Heart Hospital; and Kangdong Sacred Heart Hospital) between 2006 and 2010 were retrospectively enrolled. Univariate analysis identified significant predictive values in the following eight factors: i) Cancer stage (P<0.0001); ii) tumor size (≤4 vs. 4-6 cm, P=0.0147; and ≤4 vs. >6 cm, P<0.0001); iii) serum squamous cell carcinoma antigen level (≤2 vs. >15 ng/ml; P=0.0291); iv) lower third vaginal involvement (P<0.0001); v) hydronephrosis (P=0.0003); vi) bladder/rectum involvement (P=0.0015); vii) pelvic (P=0.0017) or para-aortic (P=0.0019) lymph node (LN) metastasis detected by imaging vs. no metastasis; and viii) pelvic LN metastasis identified by pathological analysis (P=0.0289). Furthermore, multivariate analysis determined that tumor size (≤4 vs. 4-6 cm, P= 0.0371; and ≤4 vs. >6 cm, P=0.0024) and pelvic LN metastasis determined by imaging vs. no metastasis (P=0.0499) were independent predictive variables. Therefore, tumor size and pelvic LN metastasis measured by imaging were independent predictive factors for the prognosis of advanced cervical cancer. These factors may provide more clinically significant prognostic information compared with the currently used International Federation of Gynecology and Obstetrics staging system.

show abstract

“…Cervical cancer is the second most common female cancer . A worse prognosis has been observed even in early cervical cancer with tumor diameter more than 4 cm or locally advanced cervical cancer (LACC).…”

mentioning

confidence: 99%

“…A worse prognosis has been observed even in early cervical cancer with tumor diameter more than 4 cm or locally advanced cervical cancer (LACC). Neoadjuvant chemotherapy (NACT) followed by radical surgery is a valid alternative therapeutic option to concurrent chemotherapy and radiotherapy for patients with LACC . The achievement of an optimal pathological response on surgical specimens is a strong predictor of a better clinical outcome .…”

mentioning

confidence: 99%

Simultaneous changes of magnetic resonance diffusion-weighted imaging and pathological microstructure in locally advanced cervical cancer caused by neoadjuvant chemotherapy

Feng

Bian

et al. 2014

J. Magn. Reson. Imaging

View full text Add to dashboard Cite

show abstract

Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer

Cited by 20 publications

References 0 publications

Robotic nerve-sparing radical hysterectomy for locally advanced cervical cancer after neoadjuvant chemotherapy

Robotic nerve-sparing radical hysterectomy for locally advanced cervical cancer after neoadjuvant chemotherapy

Tumor size and lymph node status determined by imaging are reliable factors for predicting advanced cervical cancer prognosis

Simultaneous changes of magnetic resonance diffusion-weighted imaging and pathological microstructure in locally advanced cervical cancer caused by neoadjuvant chemotherapy

Contact Info

Product

Resources

About